METTL7B ‐Mediated m6A Modification of PLEKHA4 Suppresses Ferroptosis via Reducing AURKA Ubiquitination to Promote Papillary Thyroid Cancer Progression
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72373 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 28.10.2026. Verfasst von Wei Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Ferroptosis, Thyroid Cancer, Papillary, Thyroid Neoplasms, Methyltransferases. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
The malignant progression of papillary thyroid carcinoma (PTC) is closely associated with the acquisition of ferroptosis resistance by tumor cells; however, the upstream regulatory mechanisms remain poorly understood. This study aims to elucidate the function and molecular mechanisms of the methyltransferase‐like 7B (METTL7B)/pleckstrin homology domain‐containing family A member 4 (PLEKHA4)/aurora kinase A (AURKA) signaling axis in ferroptosis resistance in PTC. Our results showed that PLEKHA4 was highly expressed in PTC. By binding to kelch‐like protein 12 (KLHL12), PLEKHA4 inhibited KLHL12‐mediated ubiquitination and degradation of AURKA, thereby stabilizing the AURKA protein and enhancing ferroptosis resistance in PTC cells. Upstream, METTL7B stabilized PLEKHA4 mRNA and upregulated its expression through N6‐methyladenosine (m6A) modification. Both in vitro and in vivo experiments confirmed that knockdown of METTL7B increased ferroptosis sensitivity and suppressed PTC progression. This study reveals a novel paradigm in which PLEKHA4, as an effector of m6A modification, regulates ferroptosis by interfering with ubiquitin‐mediated degradation, providing a theoretical basis for targeting this pathway in the treatment of PTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
- Department of General Surgery, Second Division, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.
- First Clinical Medical College, Fujian Medical University, Fuzhou, Fujian, China.
- Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.
ORCID-Profile: Wei Lin, Kunlin Wu, Xiangjin Chen
Förderung
- Natural Science Foundation of Fujian Province
Zitieren
APA
Lin, W., Wu, K., Chen, J., Yu, Z., Zhang, H., & Chen, X. (2026). METTL7B ‐Mediated m6A Modification of PLEKHA4 Suppresses Ferroptosis via Reducing AURKA Ubiquitination to Promote Papillary Thyroid Cancer Progression. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72373
Vancouver
Lin W, Wu K, Chen J, Yu Z, Zhang H, Chen X. METTL7B ‐Mediated m6A Modification of PLEKHA4 Suppresses Ferroptosis via Reducing AURKA Ubiquitination to Promote Papillary Thyroid Cancer Progression. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72373
BibTeX
@article{Lin2026,
author = {Lin, Wei and Wu, Kunlin and Chen, Jinshu and Yu, Zhaomei and Zhang, Huihao and Chen, Xiangjin},
title = {METTL7B ‐Mediated m6A Modification of PLEKHA4 Suppresses Ferroptosis via Reducing AURKA Ubiquitination to Promote Papillary Thyroid Cancer Progression},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72373}
}
EUVIMED